| Title |
miR-132 can inhibit glioma cells invasion and migration by target MMP16 in vitro
|
|---|---|
| Published in |
OncoTargets and therapy, November 2015
|
| DOI | 10.2147/ott.s79282 |
| Pubmed ID | |
| Authors |
Hangzhou Wang, Xue-tao Li, Chun Wu, Zhi-wu Wu, Yan-yan Li, Tian-quan Yang, Gui-lin Chen, Xue-shun Xie, Yu-lun Huang, Zi-wei Du, You-xin Zhou |
| Abstract |
Gliomas are the most common malignant primary brain tumors, and new clinical biomarkers and therapeutic targets are imminently required. MicroRNAs (miRNAs) are a novel class of small non-coding RNAs (∼22nt) involved in the regulation of various biological processes. Here, by using real-time polymerase chain reaction, miRNA-132 was found to be significantly deregulated in glioma tissues. Based on the prediction of the target genes of miR-132, we hypothesized that there is a significant association between miR-132 and matrix metalloproteinase (MMP) 16 (MT3-MMP), a protein of the MMP family. We showed that the up-expression of miR-132 inhibited cell migration and invasion in the human glioma cell lines A172, SHG44, and U87. Furthermore, the overexpression of miR-132 reduced the expression of MMP16 in A172, SHG44, and U87 cells. Taken together, our study suggested that miR-132 affects glioma cell migration and invasion by MMP16 and implicates miR-132 as a metastasis-inhibiting miRNA in gliomas. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 5 | 24% |
| Researcher | 4 | 19% |
| Student > Ph. D. Student | 3 | 14% |
| Student > Postgraduate | 3 | 14% |
| Student > Master | 2 | 10% |
| Other | 3 | 14% |
| Unknown | 1 | 5% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 33% |
| Biochemistry, Genetics and Molecular Biology | 5 | 24% |
| Agricultural and Biological Sciences | 5 | 24% |
| Engineering | 1 | 5% |
| Unknown | 3 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 April 2018.
All research outputs
#20,655,488
of 25,371,288 outputs
Outputs from OncoTargets and therapy
#1,597
of 3,016 outputs
Outputs of similar age
#215,828
of 294,808 outputs
Outputs of similar age from OncoTargets and therapy
#53
of 104 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 294,808 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 104 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.